Safety of esketamine nasal spray: Analysis of post-marketing reports submitted to the FDA adverse event reporting system in the first year on the market

INTRODUCTION: The approval of the esketamine nasal spray for treatment-resistant depression in March 2019 by the Food and Drug Administration (FDA), and few months later by the European Medicine Agency, triggered a vivid debate and many concerns, mainly because of the lack of convincing evidence on...

Descripción completa

Detalles Bibliográficos
Autores principales: Gastaldon, C., Raschi, E., Kane, J., Barbui, C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cambridge University Press 2021
Materias:
Abstract
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9471491/
http://dx.doi.org/10.1192/j.eurpsy.2021.410

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9471491/
http://dx.doi.org/10.1192/j.eurpsy.2021.410

Ejemplares similares